Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 675 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. The company has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The firm provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. The company provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Mr. Peter Anevski is the Chief Executive Officer of Progyny Inc, joining the firm since 2017.
What is the price performance of PGNY stock?
The current price of PGNY is $31, it has increased 0.71% in the last trading day.
What are the primary business themes or industries for Progyny Inc?
Progyny Inc belongs to Health Care industry and the sector is Health Care
What is Progyny Inc market cap?
Progyny Inc's current market cap is $2.4B
Is Progyny Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Progyny Inc, including 6 strong buy, 4 buy, 6 hold, 0 sell, and 6 strong sell